SR Pharma plc Announces Therapeutic Efficacy of Atu027 RNAi in pre-clinical Models of Pancreatic Cancer
SR Pharma plc announced that studies at the Charité Hospital have demonstrated the superior therapeutic efficacy of Atu027 RNAi in pre-clinical models of pancreatic cancer when compared to the standard care treatment. The data showed both inhibition of cancer growth and prevention of metastatic spread, demonstrating potent efficacy and effective systemic delivery with no adverse events. According to the compnay, Atu027 RNAi was significantly more effective in the prevention of metastases than Gemcitabine®. The novel anti-angiogenic treatment was feasible, safe and effective in vivo. The growth inhibitory and anti-metastatic effects of Atu027 RNAi in the clinically relevant in vivo model fully support further development of this substance for pancreatic cancer. A phase I clinical trial using Atu027 RNAi in patients suffering from pancreatic cancer is scheduled to start in 2007.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.